Physicians Are Reluctant to Assign Their Patients to a Clinical Trial of a New Therapy That Might Replace the Therapy They Know and Practice

(p. D1) After learning he had early stage prostate cancer, Paul Kolnik knew he wanted that cancer destroyed immediately and with as little disruption as possible to his busy life as the New York City Ballet’s photographer.

So Mr. Kolnik, 65, chose a type of radiation treatment that is raising some eyebrows in the prostate cancer field. It is more intense than standard radiation and takes much less time — five sessions over two weeks instead of 40 sessions over about two months or 28 sessions over five to six weeks.

. . .

The National Cancer Institute has just agreed to fund a clinical trial that researchers hope will settle which treatment is better. It will randomly assign 538 men to have either a short course of five intense radiation sessions over two weeks or 28 treatments over five and a half weeks, comparing outcomes for quality of life as well as disease-free survival.

But it will be at least eight years before the answers are in. In the meantime, men and their doctors are left with uncertainty.

“Ideally, we want to show five treatments (p. D4) is better,” said Dr. Rodney J. Ellis, a radiation oncologist at Case Comprehensive Cancer Center in Cleveland and the principal investigator for the trial.

One reason for the dearth of data is that prostate cancer usually grows slowly, if at all, so it can take many years to see if a treatment saved lives. It is expensive and difficult to follow patients for such a long time, and the treatments given to the men often change over a decade, making doctors wonder if the results are relevant.

Also, researchers who have tried to conduct studies comparing treatments often failed because specialists were already convinced that the method they used was best and were reluctant to assign men to other treatments. Dr. Ian Thompson of the University of Texas Health Science Center in San Antonio, said he was involved with several clinical trials that withered for that reason.

. . .

The researchers on the new study think recruitment will not be a major problem because they are comparing different courses of radiation, rather than entirely different approaches — for example, surgical removal of the prostate versus implantation of radioactive seeds in the prostate. A study to investigate those two approaches closed because investigators were able to enroll only 20 patients, Dr. Thompson said.

. . .

A few years ago, Dr. Yu and his colleagues looked at Medicare data and reported that men who had more intense radiation therapy were more likely to have urinary problems after two years than those who had the longer-course therapy.

Dr. Yu noted that his study was not a randomized trial, the gold standard, but he said the results were not reassuring. Now, though, he is not so sure the intense therapy is worse.

“In my own experience, these men have done really well,” he said. “That tells us that techniques improved, or the medical claims we evaluated were not indicative of major toxicity, or the way we and others at high-volume centers deliver radiotherapy is different.”

The lack of solid data bothers Dr. Daniel W. Lin, chief of urologic oncology at the University of Washington. When men ask him about the shorter radiation course, he tells them, “It probably can work but it doesn’t have long-term results and it hasn’t been tested against standard radiation.”

At centers like Sloan Kettering, doctors are relying on their own experience.

Dr. Michael J. Zelefsky, a radiation oncologist who treated Mr. Kolnik there, said that several years ago, 90 percent of his patients had the standard course of treatment. Now 90 percent choose the shorter course. On the basis of Sloan Kettering’s experience with several hundred men who had the intense radiation therapy over the past three years, the treatment, he said, “is emerging as a very exciting form of therapy.”

For the full story see:

Gina Kolata. “Unproven Therapy Gains Ground.” The New York Times (Tuesday, March 21, 2017 [sic]): D1 & D4.

(Note: ellipses added.)

(Note: the online version of the story has the date March 20, 2017 [sic], and has the title “Popular Prostate Cancer Therapy Is Short, Intense and Unproven.”)

California Politicians Ban Test of Sprayed Seawater That Might Reverse Global Warming

Some environmentalists are only willing to cool the planet by the pain of less consumption.

(p. A14) Elected leaders in Alameda, Calif., voted early on Wednesday [June 5, 2024] to stop scientists from testing a device that might one day be used to artificially cool the planet, overruling city staff members who had found the experiment posed no danger.

. . .

The test involved spraying tiny sea-salt particles across the flight deck of a decommissioned aircraft carrier, the U.S.S. Hornet, docked in Alameda in San Francisco Bay. Versions of that device could eventually be used to spray the material skyward, making clouds brighter so that they reflect more sunlight away from Earth. Scientists say that could help to cool the planet and to fight the effects of global warming.

. . .

“The chemical components of the saltwater solution (which is similar to seawater) being sprayed are naturally occurring in the environment,” the report said. Staff recommended that the City Council allow the experiment to continue, . . .

. . .

Some environmentalists oppose research aimed at so-called climate intervention, also known as solar geoengineering. They argue that such technology carries the risk of unintended consequences, and also takes money and attention away from efforts to reduce the use of fossil fuels, the burning of which is the underlying cause of climate change.

For the full story see:

Soumya Karlamangla and Christopher Flavelle. “Leaders in California City Halt Cloud-Brightening Test.” The New York Times (Thursday, June 6, 2024): A14.

(Note: ellipses, and bracketed date, added.)

(Note: the online version of the story has the date June 5, 2024, and has the title “California City Leaders End Cloud-Brightening Test, Overruling Staff.”)

The Joy of the Smell Test

If actionable knowledge can come for several sources, but we forbid action based on some of those sources, we will limit our effective action. In the case of health, unnecessary suffering and death will result. In previous entries I highlighted cases where dogs’ advanced ability to smell can diagnose and warn of human maladies more accurately, quicker, and cheaper than other methods. Dog-detectable maladies include Covid, epileptic seizures, and cancer. But the medical establishment underuses this source of knowledge because it is not viewed as scientifically respectable. (And perhaps also because those who practice scientifically respectable ways of knowing, benefit from limiting competition?) The passages quoted below sketch the story of a “hyperosmic” nurse who can smell a distinct odor that identifies those who have and who will have Parkinson’s. Note that follow-up research on this outside-the-box diagnostic method was not funded by governments or universities but by a private foundation founded and funded by Parkinson’s patients and their families and friends. Having a terrible disease sometimes leads to despair, sometimes to a sense of urgency.

(p. 30) As a boy, Les Milne carried an air of triumph about him, and an air of sorrow.  . . .  “We were very, very much in love,” Joy, now a flaxen-haired 72-year-old grandmother, told me recently. In a somewhat less conventional way, she also adored the way Les smelled, and this aroma of salt and musk, accented with a suggestion of leather from the carbolic soap he used at the pool, formed for her a lasting sense of who he was. “It was just him,” Joy said, a steadfast marker of his identity, no less distinctive than his face, his voice, his particular quality of mind.

Joy’s had always been an unusually sensitive nose, the inheritance, she believes, of her maternal line. Her grandmother was a “hyperosmic,” and she encouraged Joy, as a child, to make the most of her abilities, quizzing her on different varieties of rose, teaching her to distinguish the scent of the petals from the scent of the leaves from the scent of the pistils and stamens. Still, her grandmother did not think odor of any kind to be a polite topic of conversation, and however rich and enjoyable and dense with information the olfactory world might be, she urged her granddaughter to keep her experience of it to herself.

. . .

Les spent long hours in the surgical theater, which in Macclesfield had little in the way of ventilation, and Joy typically found that he came home smelling of anesthetics, antiseptics and blood. But he returned one August evening in 1982, shortly after his 32nd birthday, smelling of something new and distinctly unsavory, of some thick must. From then on, the odor never ceased, though neither Les nor almost anyone but his wife could detect it.  . . .

Les had lately begun to change in other ways, however, and soon the smell came to seem almost trivial. It was as if his personality had shifted. Les had rather suddenly become detached, ill-tempered, apathetic. He ceased helping out with many household chores; he snapped at his boys.

. . .

When he began referring to “the other person,” a shadow off to his side, she suspected a brain tumor. Eventually she prevailed upon him to see his doctor, who referred him to a neurologist in Manchester.

Parkinson’s disease is typically classed as a movement disorder, and its most familiar symptoms — tremor, rigidity, a slowing known as bradykinesia — are indeed motoric. But the disease’s autonomic, psychological and cognitive symptoms are no less terrible and commonly begin during the so-called prodrome, years before any changes in movement.

. . .

(p. 31) Feeling desperate, Joy eventually persuaded Les to go with her to a meeting of local Parkinson’s patients and their caregivers.

The room was half full by the time they arrived. Near the coat stand, Joy squeezed behind a man just as he was taking off his jacket and suddenly felt a twitch in her neck, as if some fight-or-flight instinct had been activated, and she raised her nostrils instinctively to the air. She often had this reaction to strong, unexpected scents. In this case, bizarrely, it was the disagreeable odor that had hung about her husband for the past 25 years. The man smelled just like him, Joy realized. So too did all the other patients. The implications struck her immediately.

For nearly all the recorded history of medicine and until only quite recently, smell was a central preoccupation. The “miasma” theory of disease, predominant until the end of the 19th century, held that illnesses of all kinds were spread by noxious odors. By a similar token, particular scents were understood to be curative or prophylactic. More than anything, however, odor was a tool of diagnosis.

The ancients of Greece and China confirmed tuberculosis by tossing a patient’s sputum onto hot coals and smelling the fumes. Typhoid fever has long been known to smell of baking bread; yellow fever smells of raw meat. The metabolic disorder phenylketonuria was discovered by way of the musty smell it leaves in urine, while fish-odor syndrome, or trimethylaminuria, is named for its scent.

. . .

(p. 33) Most diseases can be identified by methods more precise and ostensibly scientific than aroma, however, and we tend to treat odor in general as a sort of taboo. “A venerable intellectual tradition has associated olfaction with the primitive and the childish,” writes Mark Jenner, a professor of history at the University of York. Modern doctors are trained to diagnose by inspection, palpation, percussion and auscultation; “inhalation” is not on the list, and social norms would discourage it if it were.

During her time as a nurse, Joy had done it anyway, reflexively, and learned to detect the acetone breath that signaled an impending diabetic episode, the wet brown cardboard aroma of tuberculosis — “not wet white cardboard, because wet white cardboard smells completely different,” she explained — or the rancidness of leukemia. The notion that Parkinson’s might have a distinctive scent of its own had not occurred to her then, but when it did occur to her years later, it was hardly exotic.

She and Les worried that the normosmics of the world, unfamiliar with medical smells and disinclined to talk about odor in general, might not take her discovery very seriously. They searched for an open-minded scientist and after several weeks settled on Kunath, the Parkinson’s researcher at the University of Edinburgh. In 2012, Joy attended a public talk he gave. During the question-and-answer session, she stood to ask, “Do people with Parkinson’s smell different?” Kunath recalls. “I said, ‘Do you mean, Do people with Parkinson’s lose their sense of smell?’” (Smell loss is in fact a common early symptom of the disease.) “And she said: ‘No, no, no. I mean, Do they smell different?’ And I was just like, ‘Uh, no.’” Joy went home. Kunath returned to his usual work.

Six months later, however, at the urging of a colleague who had once been impressed by cancer-sniffing dogs, Kunath found Joy’s name and called her. She told him the story of Les’s new smell. “I think if she’d told me that, as he got Parkinson’s, he had a change in smell, or if it came afterwards, I probably wouldn’t have followed up any more,” Kunath told me. “But it’s this idea that it was years before.”

He called Perdita Barran, an analytical chemist, to ask what she made of Joy’s claims. Barran suspected Joy was simply smelling the usual odor of the elderly and infirm and misattributing it to Parkinson’s. “I knew, because we all know, that old people are more smelly than young people,” says Barran, who is now a professor of mass spectrometry at the University of Manchester. Still, Barran was personally acquainted with the oddities of olfaction. Following a bike accident, she had for several years experienced various bizarre distortions to her own sense of smell. The idea that Joy might be capable of experiencing odors that no one else could did not strike her as entirely outlandish.

She and Kunath ran a small pilot study in Edinburgh. Through Parkinson’s UK, they recruited 12 participants: six local Parkinson’s patients and six healthy controls. Each participant was asked to wear a freshly laundered T-shirt for 24 hours. The worn shirts were then cut in half down the center, and each half was placed in its own sealed plastic bag. Kunath oversaw the testing. Joy smelled the T-shirt halves at random and rated the intensity of their Parkinsonian odor. “She would find a positive one, and would say, ‘There — it’s right there. Can you not smell it?’” Kunath recalled. Neither he nor the graduate student assisting him could smell a thing.

Kunath unblinded the results at the end of the day. “We were on a little bit of a high,” he recalled. Not only had Joy correctly identified each sample belonging to a Parkinson’s patient, but she was also able, by smell, to match each sample half to its partner. Barran’s skepticism evaporated. Still, Joy’s record was not perfect. She had incorrectly identified one of the controls as a Parkinson’s patient. The researchers wondered if the sample had been contaminated, or if Joy’s nose had simply gotten tired. By Barran’s recollection, Kunath’s response was: “It’s fine! It’s one false positive!” Barran herself was slightly more cautious: Joy had mislabeled both halves of the man’s T-shirt.

Of more immediate interest, though, was the question of what was causing the smell in the first place. The odor seemed to be concentrated not in the armpits, as the researchers had anticipated, but at the neckline. It took them several weeks to realize that it perhaps came from sebum, the lipid-rich substance secreted by the skin. Sebum is among the least studied biological substances. “It is actually another waste disposal for our system,” Barran says. “But no one had ever thought that this was a bodily fluid we could use to find out about disease.”

Barran set out to analyze the sebum of Parkinson’s patients, hoping to identify the particular molecules responsible for the smell Joy detected: a chemical signature of the disease, one that could be detected by machine and could thus form the basis of a universal diagnostic test, a test that ultimately would not depend on Joy’s or anyone else’s nose. No one seemed to be interested in funding the work, though. There were no established protocols for working with sebum, and grant reviewers were unimpressed by the tiny pilot study. They also appeared to find the notion of studying a grandmother’s unusual olfactory abilities to be faintly ridiculous. The response was effectively, “Oh, this isn’t science — science is about measuring things in the blood,” Barran says.

Barran turned to other projects. After nearly a year, however, at a Parkinson’s event in Edinburgh, a familiar-looking man approached Kunath. He had served as one of the healthy controls in the pilot study. “You’re going to have to put me in the other category,” he said, according to Kunath. The man had recently been diagnosed with Parkinson’s. Kunath was stunned. Joy’s “misidentification” had not been an error, but rather an act of clairvoyance. She had diagnosed the man before medicine could do so.

Funding for a full study of Joy, the smell and its chemical components now came through. “We saw something in the news, and we thought, Wow, we’ve got to act on that!” says Samantha Hutten, the director of translational research at the Michael J. Fox Foundation. “The N.I.H. is not going to fund that. Who’s going to fund it if not us?”

. . .

(p. 51) Joy has enjoyed her fame, but the smell work also radicalized her, in its way, and she has a reputation for being a bit intransigent in her advocacy. The initial scientific skepticism toward her was of a piece, she thought, with what she already held to be the medical corps’s hopeless wrongheadedness about Parkinson’s disease. For Joy, as for many caregivers, the psychological aspects of the illness were by far the most difficult to manage, much less accept, and these happened to be precisely the symptoms neurologists seemed least interested in acknowledging, let alone addressing.  . . .

To Joy’s mind, still more proof of this medical obstinacy came from the discovery that she was not alone in her ability to smell Parkinson’s disease. When the research first began to attract attention in the media, Barran and Kunath received messages from around the world from people reporting that they, too, had noticed a change in the smell of their loved ones with Parkinson’s.
  . . .  But for the smell taboo, Joy thought, someone somewhere might have taken these people seriously, and the importance of the odor might have been realized decades sooner.

For the full story see:

Scott Sayare. “The Smell Test.” The New York Times Magazine (Sunday, June 16, 2024): 28-33, 51 & 53.

(Note: ellipses added; bold in original.)

(Note: the online version of the story has the date June 3, 2024, and has the title “The Woman Who Could Smell Parkinson’s.”)

“Troublemaker” Finally Convinced Peers That Hub Trees Distribute Resources to Kin

(p. C7) Over the years, Ms. Simard encountered no shortage of pushback. Government bureaucrats were reluctant to spend money on her recommendations. Her managers resisted changing their forestry models and perhaps “couldn’t listen to women,” labeling her a “troublemaker.” Fellow scientists challenged her research methods. This last may have originated in envy, but ultimately is an important part of the scientific process—after all, without stringent vetting, we might still believe that Vulcan is, indeed, a planet. Today Ms. Simard’s research is widely accepted. We now know that through fungal networks trees share resources, that mature trees (what she calls “hub trees” in her research, and “mother trees” when speaking to popular audiences) support seedlings, favor their kin and distribute resources, even in death. It’s a radical new understanding of plants.

For the full review, see:

Eugenia Bone. “Seeing the Forest.” The Wall Street Journal (Saturday, May 8, 2021 [sic]): C7.

(Note: the online version of the review has the date May 7, 2021 [sic], and has the title “‘Finding the Mother Tree’ Review: Seeing the Forest.”)

The book under review is:

Simard, Suzanne. Finding the Mother Tree: Discovering the Wisdom of the Forest. New York: Knopf, 2021.

Citizens with Criminal Records Are “Upset” at Liberals’ “Dehumanizing” Rhetoric in Calling Trump a “Convicted Felon”

(p. A16) Some Democratic leaders are eager to make former President Donald J. Trump’s new identity as a convicted criminal central to their pitch to voters on why he is unfit for office. At the same time, there has been a movement on the left for years to end the stigma of criminal records and point out grave issues in the country’s legal system.

That is why in the wake of the news last week that a New York jury had found Mr. Trump guilty of 34 felony counts of falsifying business records, there were especially complex and personal reactions among the millions of Americans who have also been convicted of felonies.

. . .

For Dawn Harrington, who served time on Rikers Island in New York and now directs an organization called Free Hearts for families affected by incarceration in Tennessee, watching the news coverage of Mr. Trump’s criminal conviction last week was upsetting.

She heard liberals rejoice that he was now a “convicted felon,” a term she and others have tried to persuade people not to use.

Ms. Harrington said she did time for gun possession after traveling to New York with a handgun that was registered in Tennessee.

. . .

After the Trump verdict, she also heard President Biden defend the justice system as a “cornerstone of America” that has endured for “nearly 250 years” — back to a time, Ms. Harrington noted, when slavery was legal.

The rhetoric, she thought, was “quite frankly dehumanizing to the base that we organize with,” she said.

For the full story see:

Shaila Dewan. “Among People With Criminal Records, Complex Feelings About Trump.” The New York Times (Wednesday, June 5, 2024): A16.

(Note: ellipses added.)

(Note: the online version of the story has the date June 3, 2024, and has the title “People With Criminal Records React to Trump Verdict: ‘Now You Understand’.”)

After Safe Drinking Water, Vaccines Were the Second “Most Successful Medical Interventions of the 20th Century”

(p. B11) Dr. Paul D. Parkman, whose research was instrumental in identifying the virus that causes rubella and developing a vaccine that has prevented an epidemic of the disease in the United States for more than 50 years, died on May 7 [2024] at his home in Auburn, N.Y., in the Finger Lakes region. He was 91.

. . .

In 1966, Dr. Parkman, Dr. Harry M. Meyer Jr. and their collaborators at the National Institutes of Health, including Maurice R. Hilleman, disclosed that they had perfected a vaccine to prevent rubella. Dr. Parkman and Dr. Meyer assigned their patents to the N.I.H. so that the vaccines could be manufactured, distributed and administered promptly.

“I never made a nickel from those patents because we wanted them to be freely available to everybody,” he said in an oral history interview for the N.I.H. in 2005.

President Lyndon B. Johnson thanked the researchers, noting that they were among the few who could “number themselves among those who directly and measurably advance human welfare, save precious lives, and bring new hope to the world.”

Still, after Dr. Parkman retired from the government in 1990, as director of the Food and Drug Administration’s Center for Biologics Evaluation and Research, he expressed concern about what he called the unfounded skepticism that persisted about the value of vaccines.

“With the exception of safe drinking water, vaccines have been the most successful medical interventions of the 20th century,” he wrote in 2002 in Food and Drug Administration Consumer, an agency journal.

For the full obituary see:

Sam Roberts. “Paul D. Parkman, 91, Researcher Whose Work Helped to Eliminate Rubella.” The New York Times (Friday, May 24, 2024): B11.

(Note: ellipses, and bracketed year, added.)

(Note: the online version of the obituary has the date May 21, 2024, and has the title “Dr. Paul Parkman, Who Helped to Eliminate Rubella, Dies at 91.”)

The 2002 article by Parkman mentioned above is:

Parkman, Paul D. “We Can’t Forget the Value of Vaccines.” Food and Drug Administration Consumer 36, no. 4 (July-Aug. 2002): 40.

Private-Sector Experimentation Versus Washington Inertia in the Fight for Longer Life

(p. A15) Amid today’s technological wizardry, it’s easy to forget that several decades have passed since a single innovation has dramatically raised the quality of life for millions of people. Summoning a car with one’s phone is nifty, but it pales in comparison with discovering penicillin or electrifying cities. Artificial intelligence is being heralded as the next big thing, but a cluster of scientists, technologists and investors are aiming higher. In the vernacular of Silicon Valley, where many of them are based, their goal is nothing less than disrupting death, and their story is at the center of “Immortality, Inc.” by science journalist Chip Walter.

. . .

That is the backdrop to Mr. Walter’s absorbing story, which he begins with a visit to Alcor, the Arizona-based organization that says it preserves corpses at minus 124 degrees Celsius “in an attempt to maintain brain viability after the heart stops.” (Current “patients” include baseball legend Ted Williams.) While this life-extending strategy, known as “cryonics,” is often ridiculed, the individuals profiled in “Immortality, Inc.” are high-status, highly regarded figures whose initiatives can’t be easily dismissed. What links them, writes Mr. Walter, is that “they are all troublemakers at heart.” They believe that the “conventional approaches” of most medical researchers and practitioners are, “at the very least, misguided.”

. . .

While “Immortality, Inc.” is focused on aging and the efforts to defy it, the book is also a gripping chronicle of private-sector experimentation and ingenuity in the face of inertia in Washington. “As recently as five years ago,” Mr. Walter writes, “the great pashas at [the National Institutes of Health] . . . looked upon aging research as largely crackpot.” He faults the Food and Drug Administration for refusing to classify aging as a disease. As a result, clinical trials—the foundation of medical research—can’t be conducted.

For the full review, see:

Matthew Rees. “BOOKSHELF; Birthdays Without End.” The Wall Street Journal (Monday, Jan. 27, 2020 [sic]): A15.

(Note: ellipses between paragraphs, added; ellipsis within paragraph, in original.)

(Note: the online version of the review has the date Jan. 26, 2020 [sic], and has the title “BOOKSHELF; ‘Immortality, Inc.’ Review: Birthdays Without End.”)

The book under review is:

Walter, Chip. Immortality, Inc.: Renegade Science, Silicon Valley Billions, and the Quest to Live Forever. Washington, D.C.: National Geographic, 2020.

To Save One Species of Brown Owl, the Feds Want to Shoot Hundreds of Thousands of a More Adaptable Similar-Looking Species of Brown Owl

Isn’t it interesting that many in the Pacific Northwest and in the federal government want to take guns away from self-defending citizens at the same time that they want to use large-bore shotguns to shoot hundreds of thousands of barred owls whose only sin is that, unlike the spotted owls who they resemble, they are not picky eaters?

(p. D1) In the ancient forests of the Pacific Northwest, the northern spotted owl, a rare and fragile subspecies of spotted owl, is being muscled out of its limited habitat by the barred owl, its larger and more ornery northeastern cousin. The opportunistic barred owl has been moving in on spotted owl turf for more than half a century, competing with the locals for food and space, outnumbering, out-reproducing and inevitably chasing them out of their nesting spots. Barred owls have also emerged as a threat to the California spotted owl, a closely related subspecies in the Sierra Nevada and the mountains of coastal and Southern California.

. . .

(p. D5) In a last-ditch effort to rescue the northern spotted owl from oblivion and protect the California spotted owl population, the U.S. Fish and Wildlife Service has proposed culling a staggering number of barred owls across a swath of 11 to 14 million acres in Washington, Oregon and Northern California, where barred owls — which the agency regards as invasive — are encroaching. The lethal management plan calls for eradicating up to half a million barred owls over the next 30 years, or 30 percent of the population over that time frame. The owls would be dispatched using the cheapest and most efficient methods, from large-bore shotguns with night scopes to capture and euthanasia.

. . .

The agency’s plan, outlined last fall in a draft report assessing its environmental impact that is due for final review this summer, has pitted conservationists, who say it will benefit both species, against animal supporters, who consider the proposed scale, scope and timeline unsustainable.

Last month, a coalition of 75 wildlife protection and animal welfare organizations sent a letter to Secretary of the Interior Deb Haaland urging her to scrap what they called a “colossally reckless action” that would necessitate a perpetual killing program to keep the number of barred owls in check. Wayne Pacelle, the president of Animal Wellness Action and an author of the statement, said it was dangerous for the government to start managing competition and social interaction among North American species, including ones that have expanded their range as a partial effect of “human perturbations” of the environment. “I cannot see how this succeeds politically, because of its price tag and its sweeping ambitions,” he said in an email.

Mr. Pacelle questions whether barred owls, which are indigenous to North America, truly meet the criteria for an invasive species. “This ‘invasive’ language rings familiar to me in our current political debates,” he said. “Demonize the migrants, and the harsh policy options become much easier from a moral perspective.”

The signatories argued that the current predicament warranted nonlethal control, and that the agency’s approach would lead to the wrong owls being shot and to the death of thousands of eagles, hawks and other creatures from lead poisoning. “Implementing a decades-long plan to unleash untold numbers of ‘hunters’ in sensitive forest ecosystems is a case of single-species myopia regarding wildlife control,” the letter said.

. . .

At first sight, it’s easy to mistake a spotted for a barred: Both have tuftless rounded heads, teddy bear eyes and bodies mottled brown and white. They can interbreed to produce chicks called sparred owls. But they differ in their habitat requirements. Up to four pairs of barred owls can occupy the three-to-12 square miles that one spotted couple needs, and barred owls aggressively defend their terrain. “The closer spotted owls live to barred owls, the less likely the spotted owls are to have offspring,” Dr. Wiens said. Barred owls also produce four times as many young.

Spotted owls are extremely picky eaters: In California, they eat only flying squirrels and wood rats. “Barred owls devour anything and everything,” Ms. Bloem said, . . .

For the full story see:

Franz Lidz. “The Lethal Cost of a Rescue.” The New York Times (Tuesday, April 30, 2024): D1 & D5.

(Note: ellipses added.)

(Note: the online version of the story has the date April 29, 2024, and has the title “They Shoot Owls in California, Don’t They?” Where there is a difference in wording between the versions, the passages quoted above follow the online version.)

Most Illegal Immigrants to the U.S. Correctly Believe That They Will Be Able to Stay Forever

(p. A1) Today, people from around the globe are streaming across the southern border, most of them just as eager to work. But rather than trying to elude U.S. authorities, the overwhelming majority of migrants seek out border agents, sometimes waiting hours or days in makeshift encampments, to surrender.

. . .

In December [2023] alone, more than 300,000 people crossed the southern border, a record number.

It is not just because they believe they will be able to make it across the 2,000 mile southern frontier. They are also certain that once they make it to the United States they will be able to stay.

Forever.

And by and large, they are not wrong.

For the full commentary, see:

Miriam Jordan. “Most Migrants Arrive Believing They Can Stay.” The New York Times (Thursday, February 1, 2024): A1 & A13.

(Note: ellipsis, and bracketed year, added.)

(Note: the online version of the commentary has the date Jan. 31, 2024, and has the title “One Big Reason Migrants Are Coming in Droves: They Believe They Can Stay.”)

Social Security Administration Is Lax in Stopping Fraud and Slow in Aiding Fraud Victims

(p. A1) For the past two decades, Liz Birenbaum’s 88-year-old mother, Marge, has received her Social Security check on the second Wednesday of each month. It’s her sole source of income, which pays for her room at a long-term care center, where she landed last October after having a stroke.

When the deposit didn’t arrive in January [2024], they logged into Marge’s Social Security account, where they found some startling clues: the last four digits of a bank account number that didn’t match her own, at a bank they didn’t recognize.

“Someone had gotten in,” said Ms. Birenbaum, of Chappaqua, N.Y. “Then I hit a panic button.”

It quickly became evident that a fraudster had redirected the $2,452 benefit to an unknown Citibank account. Marge, who lives in Minnesota, had never banked there. (Ms. Birenbaum requested to refer to her mother by her first name only to protect her from future fraud.)

Ms. Birenbaum immediately started making calls to set things right. When she finally connected with a Social Security representative from a local office in a Bloomington, Minn., the rep casually mentioned that this happens “all the time.”

“I was stunned,” Ms. Birenbaum said.

. . .

(p. A18) It can be a lucrative fraud, and a devastating benefit to lose. An estimated $33.5 million in benefits — intended for nearly 21,000 beneficiaries — were redirected in a five-year period ending in May 2018, according to the most recent audit from the Office of the Inspector General, an independent group responsible for overseeing investigations and audits at the agency. Another $23.9 million in fraudulent redirects were prevented before they happened over the same time period.

“Fraudsters were able to obtain sufficient information about a true beneficiary to convince the Social Security Administration that they were that beneficiary,” said Jeffrey Brown, a deputy assistant inspector general at the Office of the Inspector General, who analyzed the issue in 2019. “Once they were in the front door, they were able to change their direct deposits.”

. . .

Just months before Marge’s benefits were redirected, the O.I.G. issued a report that said the administration’s portal, called my Social Security, did not fully comply with federal requirements for identity verification: It said it didn’t go far enough to verify and validate new registrants’ identities, in all cases.

. . .

The issue would have been impossible for someone like Marge to rectify on her own. It was challenging enough for Ms. Birenbaum, a marketing consultant, and her brother, based near their mother in a Minneapolis suburb, who worked together to recover the benefits and secure Marge’s account.

Ms. Birenbaum — who reported the crime to the O.I.G. and the F.B.I. and alerted her state and federal representatives — once spent two and a half hours on hold with the Social Security Administration before connecting with a regional case worker. The rep was able to see that her mother’s direct deposit information had been altered in early December, the month before the benefits vanished.

Ms. Birenbaum’s brother visited their mother’s local Social Security office and became Marge’s “representative payee,” which allows him to handle her affairs (Social Security does not accept powers of attorney). They had to find ways to make the correction without bringing Marge to the office, which Ms. Birenbaum said would have been a “herculean task.”

Marge received the missing money on March 1, [2024] about a month and a half after they discovered the problem.

For the full story, see:

Tara Siegel Bernard. “Internet Thieves Drain Social Security Accounts.” The New York Times (Saturday, March 9, 2024): A1 & A18.

(Note: ellipses, and bracketed years, added.)

(Note: the online version of the story has the same date as the print version, and has the title “How Fraudsters Break Into Social Security Accounts and Steal Benefits.”)

As Threats Increase, Jewish New Yorkers Embrace “Their Right to Self-Defense”

(p. A17) It’s Sunday morning at Manhattan’s Westside Rifle & Pistol Range, where I’ve come for a safety class as part of my application for a license to carry a concealed firearm. I’m one of at least 10 Jewish men in the class, many wearing yarmulkes. Some wouldn’t have dreamed of setting foot in this place a year ago.

“I was born and raised a Jew, and I’ve lived in Brooklyn and Manhattan my whole life,” says Yoni Ben Ami, who declines to give his age or profession but looks to be around 30. “I’ve never been uncomfortable going around town being visibly Jewish until Oct. 7 [2023] and its aftermath.” Darren Leung, owner of the Westside range, says he’s seen an “exponential” increase in Jewish permit-seekers and members.

We’re thousands of miles from Gaza, but the FBI has warned that threats to American Jews are at an all-time high. Anti-Israel protesters regularly march through the streets, and some commit acts of intimidation and vandalism.

. . .

Minorities of all sorts have availed themselves of the Constitution’s guarantee of self-defense. The Pink Pistols, a gay gun-rights organization, was founded in 2000; the National African American Gun Association in 2015.

. . .

. . . Jewish New Yorkers have come to appreciate how fortunate they are to live in a country that protects their right to self-defense.

For the full commentary, see:

Max Raskin. “New York Jews Embrace Gun Rights.” The Wall Street Journal (Wednesday, Nov. 15, 2023): A17.

(Note: ellipses, and bracketed year, added.)

(Note: the online version of the commentary has the date November 14, 2023, and has the same title as the print version.)